Compare MTH & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTH | PTCT |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 5.7B |
| IPO Year | 1997 | 2006 |
| Metric | MTH | PTCT |
|---|---|---|
| Price | $65.63 | $72.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $83.38 | $80.65 |
| AVG Volume (30 Days) | ★ 869.1K | 786.5K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | 6.35 | ★ 7.78 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.78 | $19.02 |
| P/E Ratio | $10.50 | ★ $9.37 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $58.03 | $35.95 |
| 52 Week High | $84.54 | $87.50 |
| Indicator | MTH | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 61.69 |
| Support Level | $64.80 | $69.81 |
| Resistance Level | $75.71 | $79.59 |
| Average True Range (ATR) | 1.84 | 2.16 |
| MACD | 0.96 | 0.68 |
| Stochastic Oscillator | 77.05 | 89.38 |
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.